Endocrine manifestations of Down syndrome : Current Opinion in Endocrinology, Diabetes and Obesity (original) (raw)
GROWTH AND DEVELOPMENT: Edited by Lynne L. Levitsky
aDivision of Pediatric Endocrinology
bDivision of General Academic Pediatrics, Department of Pediatrics
cDepartment of Pediatrics, Down Syndrome Clinic, Massachusetts General Hospital for Children, Boston, Massachusetts, USA
Correspondence to Rachel Whooten, Division of Pediatric Endocrinology, Department of Pediatrics, Massachusetts General Hospital for Children, 55 Fruit Street, Boston, MA 02114, USA. E-mail: [email protected]
Current Opinion in Endocrinology & Diabetes and Obesity 25(1):p 61-66, February 2018. | DOI: 10.1097/MED.0000000000000382
Abstract
Purpose of review
To summarize the recent developments in endocrine disorders associated with Down syndrome.
Recent findings
Current research regarding bone health and Down syndrome continues to show an increased prevalence of low bone mass and highlights the importance of considering short stature when interpreting dual energy x-ray absorptiometry. The underlying cause of low bone density is an area of active research and will shape treatment and preventive measures. Risk of thyroid disease is present throughout the life course in individuals with Down syndrome. New approaches and understanding of the pathophysiology and management of subclinical hypothyroidism continue to be explored. Individuals with Down syndrome are also at risk for other autoimmune conditions, with recent research revealing the role of the increased expression of the Autoimmune Regulatory gene on 21st chromosome. Lastly, Down-syndrome-specific growth charts were recently published and provide a better assessment of growth.
Summary
Recent research confirms and expands on the previously known endocrinopathies in Down syndrome and provides more insight into potential underlying mechanisms.
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.